Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Other Non Operating Income: 2021-2024

Historic Other Non Operating Income for Amylyx Pharmaceuticals (AMLX) over the last 4 years, with Dec 2024 value amounting to -$1.2 million.

  • Amylyx Pharmaceuticals' Other Non Operating Income fell 27.66% to -$180,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$904,000, marking a year-over-year increase of 24.67%. This contributed to the annual value of -$1.2 million for FY2024, which is 83.94% down from last year.
  • As of FY2024, Amylyx Pharmaceuticals' Other Non Operating Income stood at -$1.2 million, which was down 83.94% from -$660,000 recorded in FY2023.
  • In the past 5 years, Amylyx Pharmaceuticals' Other Non Operating Income ranged from a high of -$51,000 in FY2021 and a low of -$1.2 million during FY2024.
  • In the last 3 years, Amylyx Pharmaceuticals' Other Non Operating Income had a median value of -$660,000 in 2023 and averaged -$808,333.
  • Data for Amylyx Pharmaceuticals' Other Non Operating Income shows a maximum YoY crashed of 980.39% (in 2022) over the last 5 years.
  • Over the past 4 years, Amylyx Pharmaceuticals' Other Non Operating Income (Yearly) stood at -$51,000 in 2021, then slumped by 980.39% to -$551,000 in 2022, then decreased by 19.78% to -$660,000 in 2023, then plummeted by 83.94% to -$1.2 million in 2024.